Revance's Daxxify Is Approved As Rival To Botox With Longer Efficacy
Executive Summary
The company is preparing a staged launch for the neuromodulator in the aesthetics market, with a focus on educating select dermatologists first before expanding to 4,000 physician partners.
You may also be interested in...
Many Firsts Among The Drugs That Launched In 2023
Drug launches in 2023 included some groundbreaking innovations, but that didn’t necessarily translate to quick commercial success.
Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.